ArticleTrends in immunology2001
Creating therapeutic cancer vaccines: notes from the battlefield.
Article in Trends in immunology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- The Neuroprotective Role of A2A Adenosine Purinoceptor Modulation as a Strategy Against Glioblastoma.Brain sciences · 2024Review
- Review
- Pancreatic carcinoma-specific immunotherapy using novel tumor specific cytotoxic T cells.Oncotarget · 2016Article
- Article
- Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
- Adenosine receptors and cancer.Handbook of experimental pharmacology · 2009Review
- Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant.Journal of immunology (Baltimore, Md. : 1950) · 2006Article
- Immunotherapy for lymphomas.International journal of hematology · 2003Review
- Cancer vaccines: progress reveals new complexities.The Journal of clinical investigation · 2002Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
With the identification of tumor antigens and a knowledge of how to vaccinate against them, the field of tumor immunology faces new challenges. In this article, the authors argue that successful immunotherapies of the future will activate anti-tumor T cells without inducing their anergy or apoptotic death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.